I’m not sure I would say it’s total fluff, but I would agree with you that, at this point in time, there is no material impact to the bottom line.
There needs to be clearance to sell in these countries first (now, that process should be relatively easy considering its carrying an FDA approval). I think once that clearance occurs we’ll be in a more concrete position to begin thinking about actual logistics, i.e.- production, distribution, pricing, etc.
I don’t think this will move the needle on stock price, but if they get clearance in these countries then 2 of the 3 main obstacles to sales (distribution and regulatory approval) will be taken care of. After that the third obstacle, production, becomes top priority. No point in moving to production until approvals are in place though, so at this point it’s still speculative.
